Q-omics provides the consensus-scored TP53I11 profile across patient tissues and cancer cell-line models. TP53I11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TP53I11 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TP53I11 RNA expression shows 18,970 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where TP53I11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53I11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53I11 survival associations across molecular data types. TP53I11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53I11 RNA expression–survival associations across cancer types. High TP53I11 expression shows unfavorable associations in UVM, KIRP, MESO and ACC, but favorable associations in KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TP53I11 RNA expression.
This table summarizes TP53I11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TP53I11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53I11 shows lower tumor expression in LUSC and KIRP and higher tumor expression in KIRC, LIHC, STAD and BRCA. The KIRC box plot shows higher TP53I11 RNA expression in tumor versus normal tissue (log2 FC = +1.234, t-test p < 0.001).
This table shows molecular features associated with TP53I11 in patient tissues and cancer cell lines. In patient samples, TP53I11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53I11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
